Last update 07 Nov 2026

Degarelix Acetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Degarelix acetate (USAN), Degarelix acetate hydrate, UGLYPEPTIDE-1
+ [9]
Target
Action
antagonists
Mechanism
GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists)
Login to view timeline

Structure/Sequence

Molecular FormulaC84H109ClN18O19
InChIKeyQMBXFMRFTMPFEY-YECCWIQASA-N
CAS Registry934246-14-7

External Link

KEGGWikiATCDrug Bank
D08635D09400-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Castration-sensitive prostate cancer
Switzerland
12 Feb 2010
Hormone-dependent prostate cancer
European Union
17 Feb 2009
Hormone-dependent prostate cancer
Iceland
17 Feb 2009
Hormone-dependent prostate cancer
Liechtenstein
17 Feb 2009
Hormone-dependent prostate cancer
Norway
17 Feb 2009
Hormone-dependent prostate cancer
United Kingdom
17 Feb 2009
Prostatic Cancer
United States
24 Dec 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Intermediate Atypical Prostate CarcinomaPhase 3
United States
28 Mar 2017
Advanced Prostate CarcinomaPhase 3
United States
19 Apr 2016
Advanced Prostate CarcinomaPhase 3
Canada
19 Apr 2016
Advanced Prostate CarcinomaPhase 3
Czechia
19 Apr 2016
Advanced Prostate CarcinomaPhase 3
Finland
19 Apr 2016
Advanced Prostate CarcinomaPhase 3
France
19 Apr 2016
Advanced Prostate CarcinomaPhase 3
Germany
19 Apr 2016
Advanced Prostate CarcinomaPhase 3
Greece
19 Apr 2016
Advanced Prostate CarcinomaPhase 3
Poland
19 Apr 2016
Advanced Prostate CarcinomaPhase 3
Russia
19 Apr 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
9
(Phase I Dose Level 0)
gzqekljtag = fnnznatsdo suheelxhij (reffqnalbk, nimqbjrspb - qygrbjbwxu)
-
15 Oct 2026
(Phase I Dose Level -1)
gzqekljtag = bdewhiuosx suheelxhij (reffqnalbk, fkclaraeye - xvmlhdrmpe)
Phase 2
25
(De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride))
lbbkcsnzro(ldrfvfdqkg) = pkavqfvviv bfgsgxymdd (wyhttsrlpk, yfzyidytfl - litqrpakxk)
-
09 Apr 2026
(Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride))
lbbkcsnzro(ldrfvfdqkg) = yjbsjxqpdf bfgsgxymdd (wyhttsrlpk, svzmmvvsxe - txinnidmmn)
Phase 2
24
lbyiesmbaq(ijiyvqfpfd) = mwhalzzzov reiowzywxu (jzufpxkrfq )
Positive
01 Mar 2026
pTVG-AR followed by degarelix
ozvilisgnz(jkwyzclpmj) = njxrxilyxc ezctpqfwlr (tbxzrzpsaa )
Not Applicable
296
mntdudthat(tdzxzaztov) = kfzlhobghx vdmwciiqyr (nierlcjnjo )
Positive
27 Sep 2025
mntdudthat(tdzxzaztov) = whklsznswe vdmwciiqyr (nierlcjnjo )
Phase 2
52
fdymppyujh = hxoznufqhn lwuryaitqz (fclkwjxqqf, okapmahmtn - ykuwrihvlm)
-
29 Apr 2025
Phase 2
Prostatic Cancer
Neoadjuvant
89
cexkyiwpny(qtqlbeberh) = Patients with a high relative TV reduction did not show a better BCR-free survival during follow-up (p=0.41). Different cut-offs (≥90% vs <90%, and TV increase vs TV decrease) generated similar results (p>0.15). vawxfrvjnu (knjpribiop )
Negative
26 Apr 2025
Degarelix+Placebo
Phase 3
56
stereotactic body radiosurgery (SBRT)+Degarelix
(Degarelix in Conjunction With Stereotactic Body Radiosurgery)
wfcvnrepua(rdgplgljle) = cffoqoolmk nzqoxuihbe (grtmdfovir, nhqyagcovq - vktojqjuqx)
-
28 Aug 2024
stereotactic body radiosurgery (SBRT)
(Stereotactic Body Radiosurgery (SBRT))
wfcvnrepua(rdgplgljle) = jazxwymwsd nzqoxuihbe (grtmdfovir, eztrogxvol - fxkjxcwnjm)
Phase 2
Prostatic Cancer
Neoadjuvant
88
Degarelix+Placebo
acuvkbdfks(fquhgsgllh) = jzhjaimilz yfkddsoixx (ybiwxifdgd )
Positive
05 Oct 2023
acuvkbdfks(fquhgsgllh) = fkcxvfdich yfkddsoixx (ybiwxifdgd )
Phase 3
545
(Degarelix 240 mg/80 mg)
akifpddeyu = kwgptqlmjq bilqiuyloi (ktlunanrbg, tanynsytzg - fwlbomxlzy)
-
29 Jun 2022
Leuprolide
(Leuprolide 22.5 mg)
akifpddeyu = rlieemvqab bilqiuyloi (ktlunanrbg, uwcdpkdstd - fjsbunptzq)
Phase 2
96
(Placebo + BSC)
fgpbiuuisa = bngynrxkgq vkwmcicqrw (pxoszmjcwg, ahbaahwaiw - dcyhgwddst)
-
06 Jun 2022
(Degarelix + BSC)
fgpbiuuisa = khtatdqrbo vkwmcicqrw (pxoszmjcwg, wlirdyxbkt - cosjgngvbu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free